Amycretin vs Retatrutide: Research Compared
A neutral, side-by-side look at two of the most-watched metabolic research candidates, contrasting receptor mechanism and clinical trial stage only. Both are investigational and supplied strictly for laboratory research. General information only, not legal or medical advice.
Amycretin vs retatrutide at a glance
The core difference in the amycretin vs retatrutide comparison is the receptor profile. Amycretin is described in the literature as a single-molecule agonist that targets two receptors, the GLP-1 receptor and the amylin receptor. Retatrutide is described as a triple receptor agonist that targets three, the GLP-1, GIP and glucagon receptors.
They also come from different developers and sit at different points in clinical development. Amycretin is associated with Novo Nordisk, while retatrutide is associated with Eli Lilly. Both remain investigational and neither is approved for human use in New Zealand.
This article contrasts mechanism and reported trial stage only. It does not compare outcomes, make therapeutic claims, or suggest either compound is suitable for any use in humans.
What amycretin is
Amycretin is an investigational molecule developed by Novo Nordisk. In the published literature it is characterised as a unimolecular, long-acting agonist, meaning a single molecule engineered to act on more than one receptor at once. The two receptors described are the GLP-1 receptor and the amylin receptor.
A notable feature discussed in research coverage is that amycretin has been studied in more than one form. Both a subcutaneous (injectable) form and an oral form have been reported in its development programme. This dual-form approach is one of the reasons the candidate has attracted attention among analysts following metabolic research.
Amycretin, as described in the literature
- Developer: Novo Nordisk
- Receptor targets: GLP-1 receptor and amylin receptor
- Design: single-molecule (unimolecular) agonist
- Forms studied: subcutaneous and oral
What retatrutide is
Retatrutide is an investigational peptide developed by Eli Lilly. It is described in the literature as a once-weekly agonist that acts on three receptors at the same time: the GLP-1 receptor, the GIP (glucose-dependent insulinotropic polypeptide) receptor, and the glucagon receptor. For this reason it is often referred to as a triple receptor agonist.
As a peptide, retatrutide belongs to the same broad molecular class as several other incretin-based research candidates. Its distinguishing characteristic within that class is the addition of glucagon receptor activity alongside the GLP-1 and GIP activity seen in some earlier dual agonists.
Retatrutide, as described in the literature
- Developer: Eli Lilly
- Receptor targets: GLP-1, GIP and glucagon receptors
- Design: triple receptor agonist
- Molecular class: peptide
Mechanism side by side: dual versus triple
The clearest way to frame amycretin vs retatrutide is by counting receptors. Amycretin is a dual-target agonist (GLP-1 plus amylin), while retatrutide is a triple-target agonist (GLP-1 plus GIP plus glucagon). The shared element is GLP-1 receptor activity. Everything else differs.
Amylin, the second target of amycretin, is a separate signalling pathway from the incretin receptors. Retatrutide does not engage amylin at all; instead it adds GIP and glucagon receptor activity. So although both candidates are often grouped together as next-generation metabolic molecules, their pharmacology is built on different combinations of targets.
Receptor count alone does not indicate that one molecule is better than another. Different targets produce different research profiles, and the comparison here is descriptive, not a ranking of outcomes.
Clinical trial stage of each
The two candidates sit at different, though both relatively advanced, stages of clinical development as reported through 2026. Retatrutide has been studied in a Phase 3 programme, publicly referred to under the TRIUMPH trial name, across several populations. Its developer has indicated regulatory filings are planned, with reporting pointing to a submission timeline in early 2027.
Amycretin has progressed through earlier-phase studies, and its developer has announced plans to advance the candidate into Phase 3 clinical development, including both the subcutaneous and oral forms. Exact enrolment status and start dates can change, so this stage should be read as a general snapshot rather than a fixed milestone.
Reported stage snapshot (2026)
- Retatrutide: Phase 3 programme (TRIUMPH); filing reported as planned for early 2027
- Amycretin: advancing from earlier-phase studies toward Phase 3, in both subcutaneous and oral forms
- Both: investigational only, not approved for human use in any market at the time of writing
Regulatory status in New Zealand
Neither amycretin nor retatrutide is approved by the Therapeutic Goods Administration (TGA) for use in New Zealand. At the time of writing, neither appears on the New Zealand Register of Therapeutic Goods (ARTG) as an approved product for human use. Both remain investigational research candidates.
Because they are unapproved, these compounds are not medicines you can be prescribed or purchase for human use in New Zealand. In a research setting they are handled strictly as laboratory materials. Any representation that either compound is a treatment, therapy, or weight product would be inaccurate and is not made here.
This guide is general information only and is not legal or medical advice. Regulatory status can change over time, so confirm the current position with official TGA sources.
What research use only means
Research use only means a material is supplied for laboratory and scientific investigation, not for human or veterinary use. It is not a medicine, a supplement, or a food. It is a chemical reference item intended for qualified researchers working in an appropriate setting.
Under a research-use-only framing
- No human or animal administration is intended or implied
- No dosing, protocol, or usage instructions are provided
- No therapeutic, diagnostic, or performance claims are made
- Handling, storage, and disposal follow standard laboratory practice
Framing amycretin vs retatrutide this way keeps the focus where the published evidence currently sits: on mechanism and clinical trial stage, rather than on outcomes in people, which remain under investigation.
How Synergy Bio supplies research peptides
Synergy Bio supplies research peptides to the New Zealand research community on a research-use-only basis. Products are listed as laboratory materials, not as medicines, and are not intended for human or veterinary use. This framing applies to every item in the catalogue, including investigational metabolic candidates.
How supply is handled
- Research use only: materials are for laboratory research, not human use
- Documentation: Novagen certificate of analysis (COA) available for reference
- Shipping: dispatched within New Zealand to research customers
This section is descriptive of how supply works. It does not claim any outcome, efficacy, or suitability for any purpose beyond laboratory research, and it does not recommend one research candidate over another.
Frequently asked questions
What is the difference between amycretin and retatrutide?+
The main difference is receptor profile. Amycretin is described as a single-molecule agonist targeting the GLP-1 and amylin receptors, while retatrutide is a triple receptor agonist targeting the GLP-1, GIP and glucagon receptors. They also come from different developers and sit at different clinical trial stages.
Who develops amycretin and retatrutide?+
Amycretin is associated with Novo Nordisk and retatrutide is associated with Eli Lilly. Both are investigational and remain in clinical development rather than being approved products.
Is amycretin a peptide or a small molecule?+
Amycretin is described as a single-molecule (unimolecular) agonist and has been studied in both subcutaneous (injectable) and oral forms. Retatrutide is described as a peptide. The forms and classes reported in the literature differ between the two candidates.
What clinical trial stage is each candidate at?+
As reported through 2026, retatrutide has been studied in a Phase 3 programme (TRIUMPH), with a regulatory filing reported as planned for early 2027. Amycretin has advanced from earlier-phase studies toward Phase 3. Stages can change over time.
Are amycretin or retatrutide approved in New Zealand?+
No. Neither is approved by the TGA or listed on the ARTG for human use at the time of writing. Both are investigational and are supplied strictly for laboratory research, not for human use.
Which one is better?+
This guide does not rank the two candidates for any outcome. It contrasts mechanism and clinical trial stage only. Comparisons of effect in people remain under investigation and are outside the scope of a research-use-only overview.
What does research use only mean?+
Research use only means the material is supplied for laboratory and scientific investigation, not for human or veterinary use. No dosing, protocols, or therapeutic claims are provided, and the item is not a medicine or supplement.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp